BPC-157 vs MK-677
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Body Protection Compound-157, Pentadecapeptide BPC 157
A synthetic peptide derived from a protein found in human gastric juice. Known for its remarkable tissue healing properties across multiple body systems. FDA classified as Category 2 in 2023, restricting compounding.
Also: Ibutamoren, Nutrobal
An orally active growth hormone secretagogue that mimics ghrelin. Although technically not a peptide, it is frequently discussed alongside GH peptides due to similar effects.
Key Comparison Insights
- BPC-157 is categorized as Healing, while MK-677 is Growth Hormone.
- MK-677 has stronger research evidence (Human Trials) compared to BPC-157 (Animal Studies).
Detailed Comparison
| Attribute | BPC-157 | MK-677 |
|---|---|---|
| Category | Healing | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | BPC-157 modulates the nitric oxide system, promotes angiogenesis (new blood vessel formation), and upregulates growth hormone receptors. It also interacts with the dopaminergic system and has been shown to accelerate tendon-to-bone healing by promoting collagen synthesis. | MK-677 binds to ghrelin receptors (GHSR) in the brain, stimulating sustained GH release and increasing IGF-1 levels. Unlike injectable GHRPs, it is orally bioavailable and has a long half-life providing 24-hour GH elevation. |
| Common Dosing | 250-500 mcg twice daily 1-2x daily | 10-25 mg daily Once daily, often before bed |
| Administration | Subcutaneous injection near injury site, or systemic | Oral |
| Typical Duration | 4-12 weeks in most research protocols | 8-12 weeks or longer |
| Best Time to Take | Morning and evening (or near injury site timing) | Before bed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Extensive preclinical studies demonstrate efficacy in healing tendons, ligaments, muscles, and the GI tract. Only 3 small human pilot studies exist (fewer than 30 total subjects). FDA placed BPC-157 in Category 2 in September 2023, meaning it cannot be used in compounded medications due to insufficient safety data. | Studies show increases in GH and IGF-1 levels, improved sleep quality, and increased lean body mass. However, a clinical trial was stopped early due to heart failure concerns in elderly patients. FDA lists MK-677 as having significant safety risks. Never received FDA approval. |
Frequently Asked Questions: BPC-157 vs MK-677
What is the difference between BPC-157 and MK-677?
BPC-157 is a healing peptide that a synthetic peptide derived from a protein found in human gastric juice. known for its remarkable tissue healing properties across multiple body systems. fda classified as category 2 in 2023, restricting compounding. MK-677 is a growth hormone peptide that an orally active growth hormone secretagogue that mimics ghrelin. although technically not a peptide, it is frequently discussed alongside gh peptides due to similar effects. The main differences lie in their mechanisms of action and clinical applications.
Which is better, BPC-157 or MK-677?
Neither is universally "better" - the choice depends on your specific goals. BPC-157 is typically used for healing purposes, while MK-677 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can BPC-157 and MK-677 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using BPC-157 and MK-677 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of BPC-157 and MK-677 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.